1-6 of 6
Evelyn Kuhnt
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Suboptimal dosing of rituximab in male and female patients with DLBCL

Clinical Trials & Observations
Michael Pfreundschuh, Carsten Müller, Samira Zeynalova, Evelyn Kuhnt, Martin H. J. Wiesen, Gerhard Held, Tanja Rixecker, Viola Poeschel, Carsten Zwick, Marcel Reiser, Norbert Schmitz, Niels Murawski
Journal: Blood
Blood (2014) 123 (5): 640–646.
https://doi.org/10.1182/blood-2013-07-517037
Published: 2014
Includes: Supplemental data
Journal Articles

Primary Mediastinal B Cell Lymphoma Treated with CHOP-Like Chemotherapy with or without Rituximab: 5-Year Results of the Mabthera International Trial Group (MInT) Study

Mathias Witzens-Harig, MD, Anthony D Ho, MD, Evelyn Kuhnt, Marek Trneny, MD, Michael Rieger, MD, Anders Österborg, MD, PhD, Ruth Pettengell, Robert Stevens, MD, Devinder S Gill, MB ChB, MRCP (UK), FRCPath (Lond), Jan Walewski, Markus Loeffler, Michael Pfreundschuh, MD
Journal: Blood
Blood (2012) 120 (21): 1612.
https://doi.org/10.1182/blood.V120.21.1612.1612
Published: 2012
Journal Articles

Parenthood in Long-Term Survivors After CHOEP Treatment for Aggressive Lymphoma Is Not Significantly Impaired in Comparison to the General Population. Results From the Mabthera International Trial (MInT) and the DSHNHL NHLB1 Study

Julia Meissner, MD, Sascha Dietrich, MD, Marita Ziepert, PhD, Evelyn Kuhnt, Tanja Rixecker, Mathias Witzens-Harig, MD, Michael Pfreundschuh, MD, Anthony D Ho, MD
Journal: Blood
Blood (2012) 120 (21): 3649.
https://doi.org/10.1182/blood.V120.21.3649.3649
Published: 2012
Journal Articles

Randomised Intergroup Trial of First line Treatment for young Low-Risk Patients (<61 years) with Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL) with a CHOP-like Regimen with or without the Anti-CD20 Antibody Rituximab – 6-Year Follow-up of the Mint Study of the Mabthera International Trial (MInT) Group

Michael Pfreundschuh, MD, Evelyn Kuhnt, Lorenz Trümper, MD, Anders Osterborg, MD, PhD, Marek Trneny, MD, Lois Shepherd, MD, Devinder S Gill, MD, Jan Walewski, MD, Ruth Pettengell, FRACP, PhD, Ulrich Jäger, MD, Pier Luigi Zinzani, MD, PhD, Ofer Shpilberg, MD, MPH, Stein Kvaloy, MD, Mads Hansen, MD, Rolf Stahel, MD, Noel Milpied, MD, Armando Lopez-Guillermo, MD, Sandra Grass, MD, Niels Murawski, MD, Viola Pöschel, Markus Löffler
Journal: Blood
Blood (2010) 116 (21): 111.
https://doi.org/10.1182/blood.V116.21.111.111
Published: 2010
Journal Articles

The Role of the Rituximab Partner Chemotherapy Regimen In Young Patients with Good-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL): Results of the 6-Year Follow-up of the Mint Study of the Mabthera International Trial (MInT) Group.

Niels Murawski, MD, Evelyn Kuhnt, Sandra Grass, MD, Wolfgang Hiddemann, MD, Eva Cavallin-Stahl, MD, Georg Hess, MD, Mathias Witzens-Harig, Ingrid Vasova, MD, Ulrich Jäger, MD, Michal Osowiecki, MD, Scott North, MD, Ruth Pettengell, FRACP, PhD, Viola Pöschel, Markus Löffler, Michael Pfreundschuh, MD
Journal: Blood
Blood (2010) 116 (21): 2826.
https://doi.org/10.1182/blood.V116.21.2826.2826
Published: 2010
Journal Articles

The Addition of Rituximab Eliminates the Negative Prognostic Impact of PMBCL Compared to DLBCL in Young Patients with CD20-Positive Aggressive Lymphomas Receiving a CHOP-Like Chemotherapy: Results of a Subgroup Analysis of the Mabthera International Trial Group (MInT) Study

Marek Trneny, MD, PhD, Michael Rieger, Anders Osterborg, MD, PhD, Ruth Pettengel, Darrell J White, MD, Devinder Gill, MB, FRCPath, FRACP, FRCPA, Jan Walewski, MD, Evelyn Kuhnt, Markus Loeffler, Michael Pfreundschuh, MD, PhD, Anthony D. Ho, M.D., Ph.D.
Journal: Blood
Blood (2008) 112 (11): 839.
https://doi.org/10.1182/blood.V112.11.839.839
Published: 2008